BioSpace News Archive

Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

Bausch + Lomb Corporation today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System.

April 24, 2023

·

9 min read

Drug Development

Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization

Can-Fite BioPharma Ltd today announced executive changes to support the Company’s continued success in advancing its pipeline toward commercialization through two pivotal Phase III trials in psoriasis and liver cancer.

April 24, 2023

·

6 min read

Business

NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks

Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group.

April 24, 2023

·

9 min read

Business

Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lantheus Holdings, Inc. and POINT Biopharma Global, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer (mCRPC).

April 24, 2023

·

6 min read

Drug Development

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting

ProMIS Neurosciences Inc. today announced data supporting the receptor of activated C-kinase 1 (RACK1) as a potential target in ALS and frontotemporal lobar degeneration with TPD-43-immunoreactive pathology (FTLD-TDP), and updated preclinical data from the Company’s lead candidate for AD, PMN310.

April 24, 2023

·

7 min read

Genetown

iSpecimen to Participate in the Aegis Virtual Conference on May 4, 2023

iSpecimen Inc. today announced that Tracy Curley, CEO of iSpecimen, will participate in the Aegis Conference to be held virtually on May 2-4, 2023.

April 24, 2023

·

1 min read

Erfonrilimab Clinical Trials Mechanism Of Action Insight

Immune checkpoints play an important role in the regulation of the immune response against antigens under normal conditions.

April 24, 2023

·

4 min read

Drug Development

Soligenix Submits Type A Meeting Request to U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. announced today that the Company has submitted a Type A Meeting Request to the United States (U.S.) Food and Drug Administration (FDA) to initiate formal discussions regarding the design of a second, Phase 3 pivotal study evaluating HyBryte™.

April 24, 2023

·

12 min read

Genetown

Agenus to Participate in May Investor Conferences

Agenus today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences.

April 24, 2023

·

1 min read

Genetown

Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Ironwood to Present New Data at Digestive Disease Week ® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old.

April 24, 2023

·

11 min read